journal article·2011-09

Vascular calcification: Inducers and inhibitors

Donghyun Lee

Materials Science and Engineering: B· Volume 176· Issue 15
Publisher page

Abstract

Abstract Unlike the traditional beliefs, there are mounting evidences suggesting that ectopic mineral depositions, including vascular calcification are mostly active processes, many times resembling that of the bone mineralization. Numbers of agents are involved in the differentiation of certain subpopulation of smooth muscle cells (SMCs) into the osteoblast-like entity, and the activation and initiation of extracellular matrix ossification process. On the other hand, there are factors as well, that prevent such differentiation and ectopic calcium phosphate formation. In normal physiological environments, activities of such procalcific and anticalcific regulatory factors are in harmony, prohibiting abnormal calcification from occurring. However, in certain pathophysiological conditions, such as atherosclerosis, chronic kidney disease (CKD), and diabetes, such balances are altered, resulting in abnormal ectopic mineral deposition. Understanding the factors that regulate the formation and inhibition of ectopic mineral formation would be beneficial in the development of tissue engineering strategies for prevention and/or treatment of such soft-tissue calcification. Current review focuses on the factors that seem to be clinically relevant and/or could be useful in developing future tissue regeneration strategies. Clinical utilities and implications of such factors are also discussed.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Parathyroid Disorders and Treatments · Heterotopic Ossification and Related Conditions · Dermatological and Skeletal Disorders

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Inducers and inhibitors of biomineralization: lessons from pathological calcification10.1111/j.1601-6343.2005.00345.x ↗
2. Soft-tissue calcifications: differential diagnosis and therapeutic approaches10.1097/00000637-199502000-00005 ↗
3. The mechanism of calcium deposition in soft tissues10.1159/000085689 ↗
4. Bone morphogenetic protein-7 inhibits vascular calcification induced by high vitamin D in mice10.1620/tjem.221.299 ↗
5. Vascular calcification: pathobiological mechanisms and clinical implications10.1161/01.RES.0000249379.55535.21 ↗
6. Osteogenic regulation of vascular calcification: an early perspective10.1152/ajpendo.00552.2003 ↗
7. Pathophysiology of vascular calcification: pivotal role of cellular senescence in vascular smooth muscle cells10.1016/j.exger.2010.07.005 ↗
8. Bone formation in carotid plaques: a clinicopathological study10.1161/01.STR.0000013741.41309.67 ↗
9. Vascular calcification and osteoporosis: inflammatory responses to oxidized lipids10.1093/ije/31.4.737 ↗
10. Bone morphogenetic protein expression in human atherosclerotic lesions10.1172/JCI116391 ↗
11. Vascular and other tissue calcification in peritoneal dialysis patients10.1177/089686080902902S01 ↗
12. Calcific aortic valve and spontaneous embolic stroke: a review of literature10.1016/j.jns.2009.07.018 ↗
13. Ashley · 2003
14. Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice10.1074/jbc.273.46.30427 ↗
15. MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors10.1074/jbc.M306972200 ↗
16. Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice10.1074/jbc.M308825200 ↗
17. Matrix vesicles in the fibrous cap of atherosclerotic plaque: possible contribution to plaque rupture10.1111/j.1582-4934.2008.00230.x ↗
18. Calcification of matrix vesicles in cardiac myxoma10.1111/j.1440-1827.1985.tb01441.x ↗
19. Matrix vesicles in atherosclerotic calcification
20. Calciphylaxis: an important imitator of cutaneous vasculitis10.1002/art.22616 ↗
21. Calciphylaxis with arterial calcification10.1056/NEJMicm060859 ↗
22. Calciphylaxis with normal renal and parathyroid function: not as rare as previously believed10.1001/archdermatol.2008.602 ↗
23. Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon10.1046/j.1523-1755.62.s82.15.x ↗
24. Calciphylaxis: emerging concept in vascular patients
25. Vascular calcification and uremia: what do we know?10.1159/000111827 ↗
27. Tumoral Calcinosis
28. Tumoral calcinosis associated with hypercalcemia in a patient with chronic renal failure
29. Aggressive tumoral calcinosis in an infant thoracotomy scar10.1510/icvts.2009.232116 ↗
30. Calcified maxillary cyst secondary to a foreign-body reaction at the site of a remote tooth extraction10.1177/014556131008900112 ↗
31. Calcified cysts in the upper abdomen10.3949/ccjm.77a.09050 ↗
32. Scrotal calcinosis: idiopathic or dystrophic?
33. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia10.1097/01.mnh.0000168336.67499.c0 ↗
34. Vascular calcification: mechanisms and clinical ramifications10.1161/01.ATV.0000133194.94939.42 ↗
35. Multilineage potential of cells from the artery wall10.1161/01.CIR.0000096485.64373.C5 ↗
36. TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify10.1172/JCI117205 ↗
37. cAMP stimulates osteoblast-like differentiation of calcifying vascular cells. Potential signaling pathway for vascular calcification10.1074/jbc.273.13.7547 ↗
38. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin10.1161/01.RES.84.2.166 ↗
39. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro10.1111/j.1523-1755.2004.66015.x ↗
40. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD10.1097/01.ASN.0000141960.01035.28 ↗
41. Phosphate regulation of vascular smooth muscle cell calcification10.1161/01.RES.87.7.e10 ↗
42. Vascular calcification mechanisms10.1097/01.ASN.0000145894.57533.C4 ↗
43. Calcification of bovine pericardium used in cardiac valve bioprostheses. Implications for the mechanisms of bioprosthetic tissue mineralization
44. Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies10.1161/01.RES.87.11.1055 ↗
45. Vascular calcification: in vitro evidence for the role of inorganic phosphate10.1097/01.ASN.0000081663.52165.66 ↗
46. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells10.1046/j.1523-1755.2002.00625.x ↗
47. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels10.1046/j.1523-1755.2003.00820.x ↗
48. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts10.1016/S0092-8674(00)80258-5 ↗
49. Vascular calcification and inorganic phosphate10.1053/ajkd.2001.27394 ↗
50. BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells10.1016/j.atherosclerosis.2007.11.031 ↗
51. Enhanced expression of the inorganic phosphate transporter Pit-1 is involved in BMP-2-induced matrix mineralization in osteoblast-like cells10.1359/jbmr.020603 ↗
52. Vascular smooth muscle cell calcification and SLC20 inorganic phosphate transporters: effects of PDGF, TNF-alpha, and Pi10.1007/s00424-009-0688-5 ↗
53. Stimulation of Na-dependent phosphate transport by platelet-derived growth factor in rat aortic smooth muscle cells10.1016/j.atherosclerosis.2003.12.039 ↗
54. Phosphate and vascular calcification: Emerging role of the sodium-dependent phosphate co-transporter PiT-110.1160/TH09-12-0814 ↗
55. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques10.1161/hq1201.100229 ↗
56. Adenovirus-mediated direct gene therapy with bone morphogenetic protein-2 produces bone10.1016/S8756-3282(99)00086-1 ↗
57. Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro10.1083/jcb.113.3.681 ↗
58. BMP signaling components are expressed in human fracture callus10.1016/S8756-3282(03)00191-1 ↗
59. Bone morphogenetic protein 4 (BMP4): a regulator of capsule chondrogenesis in the developing mouse inner ear10.1002/dvdy.10258 ↗
60. Inhibition of Wnt signaling by exogenous Mfrzb1 protein affects molar tooth size10.1177/00220345000790040601 ↗
61. Wnt7b activates canonical signaling in epithelial and vascular smooth muscle cells through interactions with Fzd1, Fzd10, and LRP510.1128/MCB.25.12.5022-5030.2005 ↗
62. Krüppel-like factor 4 (KLF4/GKLF) is a target of bone morphogenetic proteins and transforming growth factor beta 1 in the regulation of vascular smooth muscle cell phenotype10.1074/jbc.M211337200 ↗
63. LDL receptor-related protein LRP6 regulates proliferation and survival through the Wnt cascade in vascular smooth muscle cells10.1152/ajpheart.01173.2003 ↗
64. Regulation of in vitro vascular calcification by BMP4, VEGF and Wnt3a10.1007/s00223-007-9073-6 ↗
65. Replicative senescence of vascular smooth muscle cells enhances the calcification through initiating the osteoblastic transition10.1152/ajpheart.00455.2009 ↗
66. Aging and arterial stiffness10.1253/circj.CJ-10-0910 ↗
67. Plasma fibroblast growth factor-23 levels are independently associated with carotid artery atherosclerosis in maintenance hemodialysis patients10.1111/j.1542-4758.2010.00480.x ↗
68. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification10.1172/JCI17202 ↗
69. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein10.1038/386078a0 ↗
70. Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine10.1038/956 ↗
71. Role of the mouse ank gene in control of tissue calcification and arthritis10.1126/science.289.5477.265 ↗
72. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo10.1084/jem.20020911 ↗
73. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification10.1101/gad.12.9.1260 ↗
74. Importance of phosphorylation for osteopontin regulation of biomineralization10.1007/s00223-004-1288-1 ↗
75. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques10.1172/JCI116755 ↗
76. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques10.1161/01.ATV.14.10.1648 ↗
77. Potential roles of osteopontin and alphaVbeta3 integrin in the development of coronary artery restenosis after angioplasty
78. Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis10.1161/01.ATV.20.3.624 ↗
79. High glucose levels increase osteopontin production and pathologic calcification in rat dental pulp tissues10.1016/j.joen.2010.03.018 ↗
80. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells10.1053/ajkd.2001.24533 ↗
81. Radial artery calcification in end-stage renal disease patients is associated with deposition of osteopontin and diminished expression of alpha-smooth muscle actin10.1111/j.1440-1797.2008.00941.x ↗
82. Circulating levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk markers in patients with chronic kidney disease10.1111/j.1365-2362.2010.02271.x ↗
83. Recognition of osteopontin and related peptides by an alpha v beta 3 integrin stimulates immediate cell signals in osteoclasts10.1016/S0021-9258(18)54932-2 ↗
84. Osteopontin – a possible anchor of osteoclasts to bone
85. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification10.1016/S0002-9440(10)64482-3 ↗
86. Osteopontin facilitates angiogenesis, accumulation of osteoclasts, and resorption in ectopic bone10.1210/en.142.3.1325 ↗
87. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease10.1161/ATVBAHA.107.144824 ↗
88. Matrix-Gla protein and vascular calcification: the negative role of oral anticoagulant therapy
89. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins10.1083/jcb.200402046 ↗
90. Matrix Gla protein polymorphisms are associated with coronary artery calcification in men10.3177/jnsv.55.59 ↗
91. Role of vitamin K and Gla proteins in the pathophysiology of osteoporosis and vascular calcification10.1097/00075197-200011000-00004 ↗
92. Polymorphisms of the human matrix gla protein (MGP) gene, vascular calcification, and myocardial infarction10.1161/01.ATV.20.11.2386 ↗
93. Arterial calcifications10.1111/j.1582-4934.2010.01139.x ↗
94. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density10.1016/S0092-8674(00)80209-3 ↗
95. Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?10.1007/s00198-005-0040-7 ↗
96. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation10.1016/S0092-8674(00)81569-X ↗
97. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology10.1007/s001090100226 ↗
98. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases10.1001/jama.292.4.490 ↗
99. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption10.1359/jbmr.2000.15.1.2 ↗
100. Clinical review 165: markers of bone remodeling in metastatic bone disease10.1210/jc.2003-030910 ↗